IL18 and atrial fibrillation: Targeting key products of the activated NLRP3 inflammasome, such as IL-1β, IL-18, and TNFα, may also be a promising approach for AF management, as these cytokines are upregulated in the serum of AF and post-operative AF patients and induce arrhythmogenesis [77].